Catalytic anti-factor VIII allo-antibodies

US7507540B1 · kind B1 · utility

Assignees

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Srinivas Kaveri · Malakoff, FR
• Sébastien LACROIX-DESMAZES · Issy-les-Moulineaux, FR
• Michel Kazatchkine · Paris, FR

Key dates

• Filing date: Jul 18, 2000
• Grant date: Mar 24, 2009
• Expiry date: Feb 15, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

A method is disclosed of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor. Finally, the present invention relates to the application in therapeutics of said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor, of a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination, and of a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor.